Embolotherapy Global Market Forecast To - 2029

Publishing Date : January, 2023
Report Code : HCMD0176
Price:
Single license $4,950
Site license $6,750
Global license $9,000


Note: The report would be dispatched after confirmation of payment

Embolotherapy involves the percutaneous endovascular use of one or more of a variety of agents and has evolved as a minimally invasive procedure for controlling blood loss during complicated surgical procedures involving laparoscopic, neurovascular, uterine fibroids, arteriovenous malformations, hepatocellular carcinomas, benign prostate hyperplasia (BPH), neurovascular, intracranial and peripheral vasculatures related surgeries.

According to IQ4I analysis, the Embolotherapy global market is expected to grow at mid single digit CAGR from 2022 to 2029 to reach $6,115.9 million by 2029. The Embolotherapy market is segmented based on products, applications, procedures, end-users and geography. The Embolotherapy products market is segmented into temporary agents, permanent agents, Radioembolization, and supporting devices, among them, permanent agents held the largest share of the market in 2022 and are expected to grow at high single digit CAGR from 2022 to 2029. The radioembolization segment is expected to grow at high single digit CAGR from 2022 to 2029. Temporary agents are further sub-segmented into autologous agents and Resorbable gelatin sponges, of this, the Resorbable gelatin sponge accounted for the largest share in 2022 and is expected to grow at mid single digit CAGR from 2022 to 2029. The permanent agents market is further sub-segmented into particle agents, coils, liquid embolization agents, flow diverters and others, among which the coils segment commanded the largest share in 2022 and is expected to grow at low single digit CAGR from 2022 to 2029. The liquid embolization agents market is expected to grow at early teens CAGR from 2022 to 2029. The particle agents are further segmented into poly vinyl alcohol (PVA) and microspheres, among which the microspheres segment commanded the largest share in 2022 and is expected to grow at high single digit CAGR from 2022 to 2029. The coils are further segmented into pushable and detachable coils among which the detachable coils commanded the largest share in 2022, the segment is expected to grow at low single digit CAGR from 2022 to 2029.

The applications market is segmented into neurology, oncology, peripheral vascular diseases, urology and others, among them, the neurology segment held the largest share of 44.5% in 2022 and is expected to grow at mid single digit CAGR from 2022 to 2029. The urology segment is expected to grow at high single digit CAGR from 2022 to 2029. The neurology application market is sub-segmented into the intracranial aneurysm and arteriovenous malformation (AVM), of this, the intracranial aneurysm segment command the largest revenue in 2022, the AVM segment is expected to grow at high single digit CAGR from 2022 to 2029. The oncology market is further sub-segmented into liver cancer, lung cancer, and others, of this, the lung cancer segment commanded the largest revenue in 2022 and the market is expected to grow at high single digit CAGR from 2022 to 2029.

Based on Procedures the embolotherapy global market is segmented into Transcatheter Arterial Embolization (TAE), Transcatheter Arterial Chemoembolization (TACE), and Transcatheter Arterial Radioembolization (TARE)/Selective Internal Radiation Therapy (SIRT), among them, TAE commanded the largest share in 2022 and the market is expected to grow at mid single digit CAGR from 2022 to 2029, the TARE/SIRT segmented is expected to grow at high single digit CAGR from 2022 to 2029. The Transcatheter Arterial Chemoembolization (TACE) market is segmented into drug-eluting beads-TACE and conventional TACE, among which the cTACE commanded the largest revenue in 2022 and the market is expected to grow at mid single digit CAGR from 2022 to 2029.

The end-users market is classified into hospitals, ambulatory surgical centers and others. Among them, the hospital commanded the largest share in 2022 and is expected to grow at high single digit CAGR from 2022 to 2029. The ambulatory surgical center is expected to grow at high single digit CAGR from 2022 to 2029.

Geographically, North America is the largest market, followed by Europe and the Asia Pacific. The APAC region is the fastest-growing region and is expected to grow at high single digit CAGR from 2022 to 2029 presenting an array of growth opportunities and is likely to get the attention of new investors in the Embolotherapy market. Growth in the Asian market is attributed to the rising prevalence of lifestyle diseases and government initiatives in establishing innovative technologies and demand for sophisticated medical services.

Factors such as the growing patient population with chronic conditions increasing the demand for embolization procedures, and technology advancements are driving the market growth, whereas, acquisitions and collaborations and emerging markets are providing growth opportunities.

On the other hand, side effects, complications, and risks associated with embolization and lack of skilled and trained professionals are restraining the market growth, while increasing product recalls, competition from alternative therapies and stringent regulatory requirements for product development and approvals are threatening the market growth.

The Embolotherapy global market is a highly competitive market and all the existing players in this market are involved in developing new and advanced products to maintain their market shares. Major players in the embolotherapy market include Medtronic, PLC (Ireland), Microport Scientific (China), Boston Scientific Corporation (U.S.), Stryker (U.S.), Terumo Corporation (Japan), Penumbra, Inc. (U.S.), Sirtex (CDH) (China), Johnson & Johnson (U.S.), Balt Group (France), Kaneka Corporation (Japan), Merit Medical (U.S.), Cook Medical (U.S.), Siemens Healthineers (Varian) (Germany), and Guerbet (France).

 

  • 1     EXECUTIVE SUMMARY
  • 2     INTRODUCTION
    • 2.1     KEY TAKEAWAYS
    • 2.2     SCOPE OF THE REPORT
    • 2.3     REPORT DESCRIPTION
    • 2.4     MARKETS COVERED
    • 2.5     STAKEHOLDERS
    • 2.6     RESEARCH METHODOLOGY
      • 2.6.1     MARKET SIZE ESTIMATION
      • 2.6.2     MARKET BREAKDOWN AND DATA TRIANGULATION
      • 2.6.3     SECONDARY SOURCES
      • 2.6.4     PRIMARY SOURCES
      • 2.6.5     KEY DATA POINTS FROM SECONDARY SOURCES
      • 2.6.6     KEY DATA POINTS FROM PRIMARY SOURCES
      • 2.6.7     ASSUMPTIONS
  • 3     MARKET ANALYSIS
    • 3.1     INTRODUCTION
    • 3.2     MARKET SEGMENTATION
    • 3.3     FACTORS INFLUENCING MARKET
      • 3.3.1     DRIVERS AND OPPORTUNITIES
        • 3.3.1.1     GROWING PATIENT POPULATION WITH CHRONIC CONDITIONS INCREASING THE DEMAND FOR EMBOLIZATION PROCEDURES
        • 3.3.1.2     TECHNOLOGICAL ADVANCEMENTS
        • 3.3.1.3     ACQUISITIONS AND COLLABORATIONS AS A GROWTH STRATEGY
        • 3.3.1.4     INCREASE IN PRODUCT APPROVALS
        • 3.3.1.5     GROWTH OPPORTUNITIES IN EMERGING MARKETS
      • 3.3.2     RESTRAINTS AND THREATS
        • 3.3.2.1     SIDE EFFECTS, COMPLICATIONS, AND RISKS ASSOCIATED WITH EMBOLIZATION
        • 3.3.2.2     LACK OF SKILLED AND TRAINED PROFESSIONALS
        • 3.3.2.3     INCREASING PRODUCT RECALLS
        • 3.3.2.4     COMPETITION FROM ALTERNATIVE THERAPIES
        • 3.3.2.5     STRINGENT REGULATORY REQUIREMENTS FOR PRODUCT DEVELOPMENT AND APPROVALS
    • 3.4     REGULATORY AFFAIRS
      • 3.4.1     THE U.S.
      • 3.4.2     CHINA
      • 3.4.3     EUROPE
      • 3.4.4     JAPAN
      • 3.4.5     INDIA
    • 3.5     FUNDING
    • 3.6     DEALS
    • 3.7     PRODUCT APPROVALS AND LAUNCHES
    • 3.8     TECHNOLOGY ADVANCEMENTS
      • 3.8.1     GPX EMBOLIC DEVICE
      • 3.8.2     HYDRAULICALLY ACTUATED SOFT ROBOTIC STEERABLE MICRO-CATHETER
      • 3.8.3     SHAPE MEMORY POLYMER (SMP) TECHNOLOGY
      • 3.8.4     BIODEGRADABLE EMBOLIZATION AGENTS
      • 3.8.5     EMBOLIZATION IN PAIN MANAGEMENT OF OSTEOARTHRITIS
      • 3.8.6     INSTYLLA-HYDROGEL EMBOLIC SYSTEM (HES)
      • 3.8.7     MICROFLUIDICS IN MANUFACTURING OF MICROSPHERES
      • 3.8.8     MICROBOTS IN SWARMS FOR EMBOLIZATION
      • 3.8.9     BISMUTH (BI)-BASED LIQUID EMBOLIC AGENT
      • 3.8.10     FAIR-EMBO PROJECT
      • 3.8.11     BIOCURE-LIQIGEL AGENT
      • 3.8.12     WATER SOLUBLE POLYMERS AS EMBOLIC AGENT
      • 3.8.13     NANOPARTICLES IN TUMOR EMBOLIZATION THERAPY
      • 3.8.14     GAS EMBOLIZATION (GE) USING ACOUSTIC DROPLET VAPORIZATION(ADV) TECHNOLOGY
    • 3.9     PORTER'S FIVE FORCE ANALYSIS
      • 3.9.1     THREAT OF NEW ENTRANTS
      • 3.9.2     THREAT OF SUBSTITUTES
      • 3.9.3     COMPETITIVE RIVALRY
      • 3.9.4     BARGAINING POWER OF SUPPLIERS
      • 3.9.5     BARGAINING POWER OF BUYERS
    • 3.10     CLINICAL TRIALS
    • 3.11     MARKET SHARE ANALYSIS BY MAJOR PLAYERS
      • 3.11.1     EMBOLOTHERAPY MARKET SHARE ANALYSIS
      • 3.11.2     COILS MARKET SHARE ANALYSIS
      • 3.11.3     FLOW DIVERTERS & DISRUPTORS MARKET SHARE ANALYSIS
      • 3.11.4     RADIOEMBOLIZATION MARKET SHARE ANALYSIS
    • 3.12     VOLUME OF NEUROVASCULAR COIL-ASSISTED PROCEDURES
      • 3.12.1     NEUROVASCULAR COILS GLOBAL MARKET
    • 3.13     PRODUCT MATRIX OF SELECTED COMPANIES
  • 4     EMBOLOTHERAPY GLOBAL MARKET, BASED ON PRODUCTS
    • 4.1     INTRODUCTION
    • 4.2     TEMPORARY AGENTS
      • 4.2.1     AUTOLOGOUS AGENTS
      • 4.2.2     RESORBABLE GELATIN SPONGE
    • 4.3     PERMANENT AGENTS
      • 4.3.1     PARTICLE AGENTS
        • 4.3.1.1     POLY VINYL ALCOHOL (PVA)
        • 4.3.1.2     MICROSPHERES
      • 4.3.2     COILS
        • 4.3.2.1     PUSHABLE COILS
        • 4.3.2.2     DETACHABLE COILS
      • 4.3.3     LIQUID EMBOLIZATION AGENTS (LEAS)
      • 4.3.4     FLOW DIVERTERS & FLOW DISRUPTORS
      • 4.3.5     OTHERS
    • 4.4     RADIOEMBOLIZATION
    • 4.5     SUPPORTING DEVICES
  • 5     EMBOLOTHERAPY GLOBAL MARKET, BASED ON THE APPLICATION
    • 5.1     INTRODUCTION
    • 5.2     NEUROLOGY
      • 5.2.1     INTRACRANIAL ANEURYSM
      • 5.2.2     ARTERIOVENOUS MALFORMATIONS (AVM)
    • 5.3     ONCOLOGY
      • 5.3.1     LIVER CANCER
      • 5.3.2     LUNG CANCER
      • 5.3.3     OTHER CANCER
    • 5.4     PERIPHERAL VASCULAR DISEASES (PVD)
    • 5.5     UROLOGY
    • 5.6     OTHER APPLICATIONS
  • 6     EMBOLOTHERAPY GLOBAL MARKET, BASED ON PROCEDURE
    • 6.1     INTRODUCTION
    • 6.2     TRANSCATHETER ARTERIAL EMBOLIZATION (TAE)
    • 6.3     TRANSCATHETER ARTERIAL CHEMOEMBOLIZATION (TACE)
      • 6.3.1     DRUG-ELUTING BEADS TRANSCATHETER ARTERIAL CHEMOEMBOLIZATION (DEB-TACE)
      • 6.3.2     CONVENTIONAL TRANSARTERIAL CHEMO-EMBOLIZATION (CTACE)
    • 6.4     TRANS-ARTERIAL EMBOLIZATION(TARE)/ SELECTIVE INTERNAL RADIATION THERAPY (SIRT)
  • 7     EMBOLOTHERAPY GLOBAL MARKET, BASED ON END-USER
    • 7.1     INTRODUCTION
    • 7.2     HOSPITALS
    • 7.3     AMBULATORY SURGICAL CENTERS
    • 7.4     OTHER END-USERS
  • 8     EMBOLOTHERAPY GLOBAL MARKET, BASED ON REGION
    • 8.1     INTRODUCTION
    • 8.2     NORTH AMERICA
      • 8.2.1     U.S.
      • 8.2.2     REST OF NORTH AMERICA
    • 8.3     EUROPE
      • 8.3.1     GERMANY
      • 8.3.2     FRANCE
      • 8.3.3     ITALY
      • 8.3.4     REST OF EUROPE
    • 8.4     APAC
      • 8.4.1     JAPAN
      • 8.4.2     CHINA
      • 8.4.3     INDIA
      • 8.4.4     REST OF APAC
    • 8.5     REST OF THE WORLD
      • 8.5.1     BRAZIL
      • 8.5.2     REST OF SOUTH AMERICA
      • 8.5.3     MIDDLE EAST AND AFRICA
  • 9     COMPETITIVE LANDSCAPE
    • 9.1     INTRODUCTION
    • 9.2     APPROVAL
    • 9.3     ACQUISITION
    • 9.4     AGREEMENTS
    • 9.5     NEW PRODUCT LAUNCH
    • 9.6     OTHERS
  • 10     MAJOR COMPANIES
    • 10.1     BALT GROUP
      • 10.1.1     OVERVIEW
      • 10.1.2     FINANCIALS
      • 10.1.3     PRODUCT PORTFOLIO
      • 10.1.4     KEY DEVELOPMENTS
      • 10.1.5     BUSINESS STRATEGY
      • 10.1.6     SWOT ANALYSIS
    • 10.2     BOSTON SCIENTIFIC CORPORATION
      • 10.2.1     OVERVIEW
      • 10.2.2     FINANCIALS
      • 10.2.3     PRODUCT PORTFOLIO
      • 10.2.4     KEY DEVELOPMENTS
      • 10.2.5     BUSINESS STRATEGY
      • 10.2.6     SWOT ANALYSIS
    • 10.3     SIRTEX MEDICAL INC.
      • 10.3.1     OVERVIEW
      • 10.3.2     FINANCIALS
      • 10.3.3     PRODUCT PORTFOLIO
      • 10.3.4     KEY DEVELOPMENTS
      • 10.3.5     BUSINESS STRATEGY
      • 10.3.6     SWOT ANALYSIS
    • 10.4     JOHNSON & JOHNSON
      • 10.4.1     OVERVIEW
      • 10.4.2     FINANCIALS
      • 10.4.3     PRODUCT PORTFOLIO
      • 10.4.4     KEY DEVELOPMENTS
      • 10.4.5     BUSINESS STRATEGY
      • 10.4.6     SWOT ANALYSIS
    • 10.5     KANEKA CORPORATION
      • 10.5.1     OVERVIEW
      • 10.5.2     FINANCIALS
      • 10.5.3     PRODUCT PORTFOLIO
      • 10.5.4     KEY DEVELOPMENTS
      • 10.5.5     BUSINESS STRATEGY
      • 10.5.6     SWOT ANALYSIS
    • 10.6     MEDTRONIC, PLC
      • 10.6.1     OVERVIEW
      • 10.6.2     FINANCIALS
      • 10.6.3     PRODUCT PORTFOLIO
      • 10.6.4     KEY DEVELOPMENTS
      • 10.6.5     BUSINESS STRATEGY
      • 10.6.6     SWOT ANALYSIS
    • 10.7     MERIT MEDICAL SYSTEMS, INC
      • 10.7.1     OVERVIEW
      • 10.7.2     FINANCIALS
      • 10.7.3     PRODUCT PORTFOLIO
      • 10.7.4     KEY DEVELOPMENTS
      • 10.7.5     BUSINESS STRATEGY
      • 10.7.6     SWOT ANALYSIS
    • 10.8     PENUMBRA, INC
      • 10.8.1     OVERVIEW
      • 10.8.2     FINANCIALS
      • 10.8.3     PRODUCT PORTFOLIO
      • 10.8.4     KEY DEVELOPMENTS
      • 10.8.5     BUSINESS STRATEGY
      • 10.8.6     SWOT ANALYSIS
    • 10.9     STRYKER CORPORATION
      • 10.9.1     OVERVIEW
      • 10.9.2     FINANCIALS
      • 10.9.3     PRODUCT PORTFOLIO
      • 10.9.4     KEY DEVELOPMENTS
      • 10.9.5     BUSINESS STRATEGY
      • 10.9.6     SWOT ANALYSIS
    • 10.10     TERUMO CORPORATION
      • 10.10.1     OVERVIEW
      • 10.10.2     FINANCIALS
      • 10.10.3     PRODUCT PORTFOLIO
      • 10.10.4     KEY DEVELOPMENTS
      • 10.10.5     BUSINESS STRATEGY
      • 10.10.6     SWOT ANALYSIS

      LIST OF TABLES

      • TABLE 1     EMBOLOTHERAPY GLOBAL MARKET REVENUE, BASED ON REGION, (2021-2029) ($MN)
      • TABLE 2     NEUROVASCULAR COILS GLOBAL MARKET REVENUE, BASED ON REGION, (2021-2029) ($MN)
      • TABLE 3     NUMBER OF NEUROVASCULAR COILS UNITS SOLD GLOBALLY, BASED ON REGION (2021-2029) (NOS)
      • TABLE 4     INTRACRANIAL ANEURYSM GLOBAL PROCEDURAL VOLUME, BASED ON REGION, (2021-2029) ($MN)
      • TABLE 5     NEUROVASCULAR COIL UNITS SOLD AND INTRACRANIAL ANEURYSM PROCEDURES, BASED ON COUNTRIES (2022) (NOS)
      • TABLE 6     EMBOLOTHERAPY GLOBAL MARKET REVENUE, BASED ON PRODUCTS (2021-2029) ($MN)
      • TABLE 7     TEMPORARY AGENTS GLOBAL MARKET REVENUE, BASED ON REGION, (2021-2029) ($MN)
      • TABLE 8     TEMPORARY AGENTS GLOBAL MARKET REVENUE, BASED ON PRODUCT (2021-2029) ($MN)
      • TABLE 9     AUTOLOGOUS AGENTS GLOBAL MARKET REVENUE, BASED ON REGION, (2021-2029) ($MN)
      • TABLE 10     RESORBABLE GELATIN SPONGE GLOBAL MARKET REVENUE, BASED ON REGION (2021-2029) ($MN)
      • TABLE 11     PERMANENT AGENTS GLOBAL MARKET REVENUE, BASED ON PRODUCTS, (2021-2029) ($MN)
      • TABLE 12     PERMANENT AGENTS GLOBAL MARKET REVENUE, BASED ON REGION (2021-2029) ($MN)
      • TABLE 13     PARTICLE AGENTS GLOBAL MARKET REVENUE, BASED ON REGION, (2021-2029) ($MN)
      • TABLE 14     PARTICLE AGENTS GLOBAL MARKET REVENUE, BASED ON PRODUCTS (2021-2029) ($MN)
      • TABLE 15     POLYVINYL ALCOHOL (PVA) GLOBAL MARKET REVENUE, BASED ON REGION, (2021-2029) ($MN)
      • TABLE 16     MICROSPHERES GLOBAL MARKET REVENUE, BASED ON REGION (2021-2029) ($MN)
      • TABLE 17     COILS GLOBAL MARKET REVENUE, BASED ON REGION (2021-2029) ($MN)
      • TABLE 18     COILS GLOBAL MARKET REVENUE, BASED ON DEPLOYMENT (2021-2029) ($MN)
      • TABLE 19     PUSHABLE COILS GLOBAL MARKET REVENUE, BASED ON REGION, (2021-2029) ($MN)
      • TABLE 20     DETACHABLE COILS GLOBAL MARKET REVENUE, BASED ON REGION (2021-2029) ($MN)
      • TABLE 21     LIQUID EMBOLIZATION AGENTS GLOBAL MARKET REVENUE, BASED ON REGION, (2021-2029) ($MN)
      • TABLE 22     FLOW DIVERTERS & FLOW DISRUPTORS GLOBAL MARKET REVENUE, BASED ON REGION, (2021-2029) ($MN)
      • TABLE 23     OTHER GLOBAL MARKET REVENUE, BASED ON REGION, (2021-2029) ($MN)
      • TABLE 24     RADIOEMBOLIZATION GLOBAL MARKET REVENUE, BASED ON REGION, (2021-2029) ($MN)
      • TABLE 25     SUPPORTING DEVICES GLOBAL MARKET REVENUE, BASED ON REGION (2021-2029) ($MN)
      • TABLE 26     EMBOLOTHERAPY GLOBAL MARKET REVENUE, BASED ON APPLICATION (2021-2029) ($MN)
      • TABLE 27     NEUROLOGY GLOBAL MARKET REVENUE, BASED ON REGION (2021-2029) ($MN)
      • TABLE 28     NEUROLOGY GLOBAL MARKET REVENUE, BASED ON INDICATION (2021-2029) ($MN)
      • TABLE 29     INTRACRANIAL ANEURYSM GLOBAL MARKET REVENUE, BASED ON REGION, (2021-2029) ($MN)
      • TABLE 30     ARTERIOVENOUS MALFORMATIONS (AVM) GLOBAL MARKET REVENUE, BASED ON REGION, (2021-2029) ($MN)
      • TABLE 31     ONCOLOGY GLOBAL MARKET REVENUE, BASED ON REGION, (2021-2029) ($MN)
      • TABLE 32     ONCOLOGY GLOBAL MARKET REVENUE, BASED ON INDICATION (2021-2029) ($MN)
      • TABLE 33     LIVER CANCER GLOBAL MARKET REVENUE, BASED ON REGION, (2021-2029) ($MN)
      • TABLE 34     LUNG CANCER GLOBAL MARKET REVENUE, BASED ON REGION, (2021-2029) ($MN)
      • TABLE 35     OTHER CANCER GLOBAL MARKET REVENUE, BASED ON REGION, (2021-2029) ($MN)
      • TABLE 36     PERIPHERAL VASCULAR DISEASES (PVD) GLOBAL MARKET REVENUE, BASED ON REGION (2021-2029) ($MN)
      • TABLE 37     UROLOGY GLOBAL MARKET REVENUE, BASED ON REGION (2021-2029) ($MN)
      • TABLE 38     OTHER APPLICATIONS GLOBAL MARKET REVENUE, BASED ON REGION (2021-2029) ($MN)
      • TABLE 39     EMBOLOTHERAPY GLOBAL MARKET REVENUE, BASED ON PROCEDURE (2021-2029) ($MN)
      • TABLE 40     TRANSCATHETER ARTERIAL EMBOLIZATION (TAE) GLOBAL MARKET REVENUE, BASED ON REGION (2021-2029) ($MN)
      • TABLE 41     TRANSCATHETER ARTERIAL CHEMOEMBOLIZATION (TACE) GLOBAL MARKET REVENUE, BASED ON REGION (2021-2029) ($MN)
      • TABLE 42     TRANSCATHETER ARTERIAL CHEMOEMBOLIZATION (TACE) GLOBAL MARKET REVENUE, BASED ON THERAPY AGENT (2021-2029) ($MN)
      • TABLE 43     DRUG-ELUTING BEADS TRANSCATHETER ARTERIAL CHEMOEMBOLIZATION (DEB-TACE)GLOBAL MARKET REVENUE, BASED ON REGION (2021-2029) ($MN)
      • TABLE 44     CONVENTIONAL TRANSARTERIAL CHEMO-EMBOLIZATION (CTACE) GLOBAL MARKET REVENUE, BASED ON REGION (2021-2029) ($MN)
      • TABLE 45     SELECTIVE INTERNAL RADIATION THERAPY (SIRT) GLOBAL MARKET REVENUE, BASED ON REGION, (2021-2029) ($MN)
      • TABLE 46     TAE AND DEB-TACE PRODUCTS MATRIX
      • TABLE 47     EMBOLOTHERAPY GLOBAL MARKET REVENUE, BASED ON END-USER (2021-2029) ($MN)
      • TABLE 48     HOSPITAL GLOBAL MARKET REVENUE, BASED ON REGION (2021-2029) ($MN)
      • TABLE 49     AMBULATORY SURGICAL CENTERS GLOBAL MARKET REVENUE, BASED ON REGION (2021-2029) ($MN)
      • TABLE 50     OTHER END-USER GLOBAL MARKET REVENUE, BASED ON REGION (2021-2029) ($MN)
      • TABLE 51     EMBOLOTHERAPY GLOBAL MARKET REVENUE, BASED ON REGION, (2021-2029) ($MN)
      • TABLE 52     NORTH AMERICAN EMBOLOTHERAPY MARKET REVENUE, BASED ON PRODUCTS (2021-2029) ($MN)
      • TABLE 53     NORTH AMERICAN TEMPORARY AGENTS MARKET REVENUE, BASED ON PRODUCTS (2021-2029) ($MN)
      • TABLE 54     NORTH AMERICAN PERMANENT AGENTS MARKET REVENUE, BASED ON PRODUCTS (2021-2029) ($MN)
      • TABLE 55     NORTH AMERICAN PARTICLE AGENTS MARKET REVENUE, BASED ON PRODUCTS (2021-2029) ($MN)
      • TABLE 56     NORTH AMERICAN COILS MARKET REVENUE, BASED ON DEPLOYMENT (2021-2029) ($MN)
      • TABLE 57     NORTH AMERICAN EMBOLOTHERAPY MARKET REVENUE, BASED ON APPLICATION, (2021-2029) ($MN)
      • TABLE 58     NORTH AMERICAN NEUROLOGY MARKET REVENUE, BASED ON INDICATION (2021-2029) ($MN)
      • TABLE 59     NORTH AMERICAN ONCOLOGY MARKET REVENUE, BASED ON INDICATION, (2021-2029) ($MN)
      • TABLE 60     NORTH AMERICAN EMBOLOTHERAPY MARKET REVENUE, BASED ON PROCEDURE, (2021-2029) ($MN)
      • TABLE 61     NORTH AMERICAN TACE MARKET REVENUE, BASED ON THERAPY AGENT (2021-2029) ($MN)
      • TABLE 62     NORTH AMERICAN EMBOLOTHERAPY MARKET REVENUE, BASED ON END-USER (2021-2029) ($MN)
      • TABLE 63     NORTH AMERICA EMBOLOTHERAPY MARKET REVENUE, BASED ON COUNTRY (2021-2029) ($MN)
      • TABLE 64     EUROPEAN EMBOLOTHERAPY MARKET REVENUE, BASED ON PRODUCTS (2021-2029) ($MN)
      • TABLE 65     EUROPEAN TEMPORARY AGENTS MARKET REVENUE, BASED ON PRODUCTS (2021-2029) ($MN)
      • TABLE 66     EUROPEAN PERMANENT AGENTS MARKET REVENUE, BASED ON PRODUCTS (2021-2029) ($MN)
      • TABLE 67     EUROPEAN PARTICLE AGENTS MARKET REVENUE, BASED ON PRODUCTS (2021-2029) ($MN)
      • TABLE 68     EUROPEAN COILS MARKET REVENUE, BASED ON DEPLOYMENT (2021-2029) ($MN)
      • TABLE 69     EUROPEAN EMBOLOTHERAPY MARKET REVENUE, BASED ON APPLICATION, (2021-2029) ($MN)
      • TABLE 70     EUROPEAN NEUROLOGY MARKET REVENUE, BASED ON INDICATION (2021-2029) ($MN)
      • TABLE 71     EUROPEAN ONCOLOGY MARKET REVENUE, BASED ON INDICATION, (2021-2029) ($MN)
      • TABLE 72     EUROPEAN EMBOLOTHERAPY MARKET REVENUE, BASED ON PROCEDURE, (2021-2029) ($MN)
      • TABLE 73     EUROPEAN TACE MARKET REVENUE, BASED ON THERAPY AGENT (2021-2029) ($MN)
      • TABLE 74     EUROPE EMBOLOTHERAPY MARKET REVENUE, BASED ON END-USER (2021-2029) ($MN)
      • TABLE 75     EUROPEAN EMBOLOTHERAPY MARKET REVENUE, BASED ON COUNTRY (2021-2029) ($MN)
      • TABLE 76     ASIA-PACIFIC EMBOLOTHERAPY MARKET REVENUE, BASED ON PRODUCTS (2021-2029) ($MN)
      • TABLE 77     ASIA-PACIFIC TEMPORARY AGENTS MARKET REVENUE, BASED ON PRODUCT (2021-2029) ($MN)
      • TABLE 78     ASIA-PACIFIC PERMANENT AGENTS MARKET REVENUE, BASED ON PRODUCTS (2021-2029) ($MN)
      • TABLE 79     ASIA-PACIFIC PARTICLE AGENTS MARKET REVENUE, BASED ON PRODUCTS (2021-2029) ($MN)
      • TABLE 80     ASIA-PACIFIC COILS MARKET REVENUE, BASED ON DEPLOYMENT (2021-2029) ($MN)
      • TABLE 81     ASIA-PACIFIC EMBOLOTHERAPY MARKET REVENUE, BASED ON APPLICATION, (2021-2029) ($MN)
      • TABLE 82     ASIA-PACIFIC NEUROLOGY MARKET REVENUE, BASED ON INDICATION (2021-2029) ($MN)
      • TABLE 83     ASIA-PACIFIC ONCOLOGY MARKET REVENUE, BASED ON INDICATION, (2021-2029) ($MN)
      • TABLE 84     ASIA-PACIFIC EMBOLOTHERAPY MARKET REVENUE, BASED ON PROCEDURE, (2021-2029) ($MN)
      • TABLE 85     ASIA-PACIFIC TACE MARKET REVENUE, BASED ON THERAPY AGENT (2021-2029) ($MN)
      • TABLE 86     ASIA-PACIFIC EMBOLOTHERAPY MARKET REVENUE, BASED ON END-USER (2021-2029) ($MN)
      • TABLE 87     ASIA-PACIFIC EMBOLOTHERAPY MARKET REVENUE, BASED ON COUNTRY (2021-2029) ($MN)
      • TABLE 88     ROW EMBOLOTHERAPY MARKET REVENUE, BASED ON PRODUCTS (2021-2029) ($MN)
      • TABLE 89     ROW TEMPORARY AGENTS MARKET REVENUE, BASED ON PRODUCT (2021-2029) ($MN)
      • TABLE 90     ROW PERMANENT AGENTS MARKET REVENUE, BASED ON PRODUCTS (2021-2029) ($MN)
      • TABLE 91     ROW PARTICLE AGENTS MARKET REVENUE, BASED ON PRODUCTS (2021-2029) ($MN)
      • TABLE 92     ROW COILS MARKET REVENUE, BASED ON DEPLOYMENT (2021-2029) ($MN)
      • TABLE 93     ROW EMBOLOTHERAPY MARKET REVENUE, BASED ON APPLICATION, (2021-2029) ($MN)
      • TABLE 94     ROW NEUROLOGY MARKET REVENUE, BASED ON INDICATION (2021-2029) ($MN)
      • TABLE 95     ROW ONCOLOGY MARKET REVENUE, BASED ON INDICATION, (2021-2029) ($MN)
      • TABLE 96     ROW EMBOLOTHERAPY MARKET REVENUE, BASED ON PROCEDURE, (2021-2029) ($MN)
      • TABLE 97     ROW TACE MARKET REVENUE, BASED ON THERAPY AGENTS (2021-2029) ($MN)
      • TABLE 98     ROW EMBOLOTHERAPY MARKET REVENUE, BASED ON END-USER (2021-2029) ($MN)
      • TABLE 99     ROW EMBOLOTHERAPY MARKET REVENUE, BASED ON COUNTRY (2021-2029) ($MN)
      • TABLE 100     APPROVALS (2020-2022)
      • TABLE 101     ACQUISITION (2020-2022)
      • TABLE 102     AGREEMENTS (2020-2022)
      • TABLE 103     NEW PRODUCT LAUNCH (2020-2022)
      • TABLE 104     OTHERS (2020-2022)
      • TABLE 105     BOSTON SCIENTIFIC CORP.: TOTAL REVENUE AND R&D EXPENSES, (2020-2022)(Q3) ($MN)
      • TABLE 106     BOSTON SCIENTIFIC CORP.: TOTAL REVENUE, BASED ON SEGMENTS, (2020-2022)(Q3) ($MN)
      • TABLE 107     BOSTON SCIENTIFIC CORP.: CARDIOVASCULAR SUB-SEGMENT TOTAL REVENUE, (2022)(Q3) ($MN)
      • TABLE 108     BOSTON SCIENTIFIC CORP.: TOTAL REVENUE, BASED ON GEOGRAPHY, (2020-2022) (Q3) ($MN)
      • TABLE 109     JOHNSON & JOHNSON: TOTAL REVENUE AND R&D EXPENSES, (2020-2022) (Q2)($MN)
      • TABLE 110     JOHNSON & JOHNSON: TOTAL REVENUE, BASED ON SEGMENTS, (2020-2022) (Q2) ($MN)
      • TABLE 111     JOHNSON & JOHNSON: TOTAL REVENUE, BASED ON GEOGRAPHY, (2020-2022) (Q2) ($MN)
      • TABLE 112     KANEKA CORPORATION: TOTAL REVENUE AND R&D EXPENSES, (2020-2022) (Q2) ($MN)
      • TABLE 113     KANEKA CORPORATION: TOTAL REVENUE, BASED ON SEGMENTS, (2020-2022) (Q2) ($MN)
      • TABLE 114     KANEKA CORPORATION: TOTAL REVENUE, BASED ON GEOGRAPHY, (2020-2022) (Q2) ($MN)
      • TABLE 115     MEDTRONIC, PLC: TOTAL REVENUE AND R&D EXPENSES, (2020-2022) (Q2) ($MN)
      • TABLE 116     MEDTRONIC, PLC: TOTAL REVENUE, BASED ON SEGMENTS, (2020-2022) (Q2) ($MN)
      • TABLE 117     MEDTRONIC, PLC: CARDIOVASCULAR TOTAL REVENUE, BASED ON SUB-SEGMENTS, (2020-2022) (Q2) ($MN)
      • TABLE 118     MEDTRONIC, PLC: NEUROSCIENCES TOTAL REVENUE, BASED ON SUB-SEGMENTS, (2020-2022) (Q2) ($MN)
      • TABLE 119     MEDTRONIC, PLC: TOTAL REVENUE, BASED ON GEOGRAPHY, (2020-2022) (Q2) ($MN)
      • TABLE 120     MERIT MEDICAL SYSTEMS, INC: TOTAL REVENUE AND R&D EXPENSES, (2020-2022)(Q3) ($MN)
      • TABLE 121     MERIT MEDICAL SYSTEMS, INC: TOTAL REVENUE, BASED ON SEGMENTS, (2020-2022) (Q3) ($MN)
      • TABLE 122     MERIT MEDICAL SYSTEMS, INC: CARDIOVASCULAR TOTAL REVENUE, BASED ON SUB-SEGMENTS, (2020-2022)(Q3) ($MN)
      • TABLE 123     MERIT MEDICAL SYSTEMS, INC: TOTAL REVENUE, BASED ON GEOGRAPHY, (2020-2022)(Q3) ($MN)
      • TABLE 124     PENUMBRA, INC: TOTAL REVENUE AND R&D EXPENSES, (2020-2022) (Q3) ($MN)
      • TABLE 125     PENUMBRA, INC: TOTAL REVENUE, BASED ON SEGMENTS, (2020-2022) (Q3) ($MN)
      • TABLE 126     PENUMBRA, INC.: TOTAL REVENUE, BASED ON GEOGRAPHY, (2020-2022) (Q3)($MN)
      • TABLE 127     STRYKER CORPORATION: TOTAL REVENUE AND R&D EXPENSES, (2020-2022) (Q3) ($MN)
      • TABLE 128     STRYKER CORPORATION: TOTAL REVENUE, BASED ON SEGMENTS, (2020-2022) (Q3) ($MN)
      • TABLE 129     STRYKER CORPORATION: TOTAL REVENUE, BASED ON SUB-SEGMENTS, (2020-2022)(Q3) ($MN)
      • TABLE 130     STRYKER CORPORATION: TOTAL REVENUE, BASED ON GEOGRAPHY, (2020-2022) (Q3) ($MN)
      • TABLE 131     TERUMO CORPORATION: TOTAL REVENUE AND R&D EXPENSES, (2020-2022) (Q2) ($MN)
      • TABLE 132     TERUMO CORPORATION: TOTAL REVENUE, BASED ON SEGMENTS, (2020-2022) (Q2) ($MN)
      • TABLE 133     TERUMO CORPORATION: TOTAL REVENUE, BASED ON GEOGRAPHY, (2020-2022) (Q2) ($MN)

      LIST OF FIGURES

      • FIGURE 1     EMBOLOTHERAPY GLOBAL MARKET REVENUE, BASED ON REGION (2021-2029) ($MN)
      • FIGURE 2     RESEARCH METHODOLOGY: EMBOLOTHERAPY GLOBAL MARKET
      • FIGURE 3     EMBOLOTHERAPY GLOBAL MARKET: TOP-DOWN AND BOTTOM-UP APPROACH
      • FIGURE 4     EMBOLOTHERAPY GLOBAL MARKET: FORECASTING MODEL
      • FIGURE 5     EMBOLOTHERAPY GLOBAL MARKET: MARKET BREAKDOWN AND DATA TRIANGULATION
      • FIGURE 6     EMBOLOTHERAPY GLOBAL MARKET SEGMENTATION
      • FIGURE 7     EMBOLOTHEAPY PRODUCTS GLOBAL MARKET SEGMENTATION
      • FIGURE 8     EMBOLOTHEAPY APPLICATION GLOBAL MARKET SEGMENTATION
      • FIGURE 9     EMBOLOTHEAPY PROCEDURES GLOBAL MARKET SEGMENTATION
      • FIGURE 10     MARKET DYNAMICS
      • FIGURE 11     EMBOLOTHERAPY GLOBAL MARKET: PORTER'S ANALYSIS
      • FIGURE 12     CLINICAL TRIALS OF EMBOLOTHERAPY BASED ON PHASES
      • FIGURE 13     CLINICAL TRIALS OF EMBOLOTHERAPY BASED ON CONDITION
      • FIGURE 14     EMBOLOTHERAPY GLOBAL MARKET SHARE ANALYSIS BY MAJOR PLAYERS, 2022 (%)
      • FIGURE 15     COILS GLOBAL MARKET SHARE ANALYSIS BY MAJOR PLAYERS, 2022 (%)
      • FIGURE 16     FLOW DIVERTERS & DISRUPTORS GLOBAL MARKET SHARE ANALYSIS BY MAJOR PLAYERS, 2022 (%)
      • FIGURE 17     RADIOEMBOLIZATION GLOBAL MARKET SHARE ANALYSIS BY MAJOR PLAYERS, 2022 (%)
      • FIGURE 18     NEUROVASCULAR COILS NO. OF UNITS SOLD, BASED ON REGION AND COUNTRIES, (2022) (NOS)
      • FIGURE 19     INTRACRANIAL ANEURYSM NO. OF PROCEDURES, BASED ON REGION AND COUNTRIES, (2022) (NOS)
      • FIGURE 20     EMBOLOTHEAPY GLOBAL MARKET SHARE, BASED ON PRODUCT, (2022 V/S 2029) (%)
      • FIGURE 21     TEMPORARY AGENTS GLOBAL MARKET SHARE, BASED ON REGION, (2022 V/S 2029) (%)
      • FIGURE 22     TEMPORARY AGENTS GLOBAL MARKET SHARE, BASED ON PRODUCTS (2022 V/S 2029) (%)
      • FIGURE 23     RESORBABLE GELATIN SPONGE GLOBAL MARKET SHARE, BASED ON REGION, (2022 V/S 2029) (%)
      • FIGURE 24     PERMANENT AGENTS GLOBAL MARKET SHARE, BASED ON PRODUCT, (2022 V/S 2029) (%)
      • FIGURE 25     PERMANENT AGENTS GLOBAL MARKET SHARE, BASED ON REGION, (2022 V/S 2029) (%)
      • FIGURE 26     PARTICLE AGENTS GLOBAL MARKET SHARE, BASED ON REGION, (2022 V/S 2029) (%)
      • FIGURE 27     PARTICLE AGENTS GLOBAL MARKET SHARE, BASED ON PRODUCTS (2022 V/S 2029) (%)
      • FIGURE 28     POLYVINYL ALCOHOL (PVA) GLOBAL MARKET SHARE, BASED ON REGION, (2022 V/S 2029) (%)
      • FIGURE 29     COILS GLOBAL MARKET SHARE, BASED ON REGION, (2022 V/S 2029) (%)
      • FIGURE 30     COILS GLOBAL MARKET SHARE, BASED ON DEPLOYMENT (2022 V/S 2029) (%)
      • FIGURE 31     PUSHABLE COILS GLOBAL MARKET SHARE, BASED ON REGION, (2022 V/S 2029) (%)
      • FIGURE 32     DETACHABLE COILS GLOBAL MARKET SHARE, BASED ON REGION, (2022 V/S 2029) (%)
      • FIGURE 33     LIQUID EMBOLIZATION AGENTS GLOBAL MARKET SHARE, BASED ON REGION, (2022 V/S 2029) (%)
      • FIGURE 34     EMBOLOTHERAPY GLOBAL MARKET SHARE, BASED ON APPLICATION (2022) (%)
      • FIGURE 35     NEUROLOGY GLOBAL MARKET SHARE, BASED ON REGION, (2022 V/S 2029) (%)
      • FIGURE 36     NEUROLOGY GLOBAL MARKET SHARE, BASED ON INDICATION (2022 V/S 2029) (%)
      • FIGURE 37     INTRACRANIAL ANEURYSM GLOBAL MARKET SHARE, BASED ON REGION, (2022 V/S 2029) (%)
      • FIGURE 38     ARTERIOVENOUS MALFORMATIONS (AVM) GLOBAL MARKET SHARE, BASED ON REGION, (2022 V/S 2029) (%)
      • FIGURE 39     ONCOLOGY GLOBAL MARKET SHARE, BASED ON INDICATION (2022 V/S 2029) (%)
      • FIGURE 40     PERIPHERAL VASCULAR DISEASES (PVD) GLOBAL MARKET SHARE, BASED ON REGION, (2022 V/S 2029) (%)
      • FIGURE 41     EMBOLOTHERAPY GLOBAL MARKET SHARE, BASED ON PROCEDURE, (2022 V/S 2029) (%)
      • FIGURE 42     TRANSCATHETER ARTERIAL EMBOLIZATION (TAE) GLOBAL MARKET SHARE, BASED ON REGION, (2022 V/S 2029) (%)
      • FIGURE 43     TRANSCATHETER ARTERIAL CHEMOEMBOLIZATION (TACE) GLOBAL MARKET SHARE, BASED ON THERAPY AGENT, (2022 V/S 2029) (%)
      • FIGURE 44     CONVENTIONAL TRANSARTERIAL CHEMO-EMBOLIZATION (CTACE) GLOBAL MARKET SHARE, BASED ON REGION, (2022 V/S 2029) (%)
      • FIGURE 45     EMBOLOTHERAPY GLOBAL MARKET SHARE, BASED ON END-USER (2022 V/S 2029) (%)
      • FIGURE 46     HOSPITALS GLOBAL MARKET SHARE, BASED ON REGION, (2022 V/S 2029) (%)
      • FIGURE 47     EMBOLOTHERAPY GLOBAL MARKET REVENUE, BASED ON REGION (2021-2029) ($MN) CAGR (%)
      • FIGURE 48     EMBOLOTHERAPY GLOBAL MARKET SHARE, BASED ON REGIONAL MARKET REVENUE (2022) (%) ($MN)
      • FIGURE 49     NORTH AMERICAN EMBOLOTHERAPY MARKET SHARE, BASED ON PRODUCT, (2022 V/S 2029) (%)
      • FIGURE 50     NORTH AMERICAN TEMPORARY AGENTS MARKET SHARE, BASED ON PRODUCT (2022 V/S 2029) (%)
      • FIGURE 51     NORTH AMERICAN PERMANENT AGENTS MARKET SHARE, BASED ON PRODUCTS (2022 V/S 2029) (%)
      • FIGURE 52     NORTH AMERICAN PARTICLE AGENTS MARKET SHARE, BASED ON PRODUCTS (2022 V/S 2029) (%)
      • FIGURE 53     NORTH AMERICA COILS MARKET SHARE, BASED ON DEPLOYMENT, (2022 V/S 2029) (%)
      • FIGURE 54     NORTH AMERICAN EMBOLOTHERAPY MARKET SHARE, BASED ON APPLICATION, (2022) (%)
      • FIGURE 55     NORTH AMERICAN NEUROLOGY MARKET SHARE, BASED ON INDICATION, (2022 V/S 2029) (%)
      • FIGURE 56     NORTH AMERICAN EMBOLOTHERAPY MARKET SHARE, BASED ON INDICATION, (2022 V/S 2029) (%)
      • FIGURE 57     NORTH AMERICAN EMBOLOTHERAPY MARKET SHARE, BASED ON PROCEDURE, (2022 V/S 2029) (%)
      • FIGURE 58     NORTH AMERICAN TACE MARKET SHARE, BASED ON THERAPY AGENTS, (2022 V/S 2029) (%)
      • FIGURE 59     NORTH AMERICAN EMBOLOTHERAPY MARKET SHARE, BASED ON END-USER (2022 V/S 2029) (%)
      • FIGURE 60     NORTH AMERICA EMBOLOTHERAPY MARKET SHARE, BASED ON COUNTRY (2022 V/S 2029) (%)
      • FIGURE 61     U.S. EMBOLOTHERAPY MARKET REVENUE, BASED ON PRODUCT AND APPLICATION (2022 V/S 2029) ($MN)
      • FIGURE 62     U.S. EMBOLOTHERAPY MARKET REVENUE, BASED ON PROCEDURE AND END-USER (2022 V/S 2029) ($MN)
      • FIGURE 63     REST OF NORTH AMERICA EMBOLOTHERAPY MARKET REVENUE, BASED ON PRODUCT AND APPLICATION (2022 V/S 2029) ($MN)
      • FIGURE 64     REST NORTH AMERICA EMBOLOTHERAPY MARKET REVENUE, BASED ON PROCEDURE AND END-USER (2022 V/S 2029) ($MN)
      • FIGURE 65     EUROPEAN EMBOLOTHERAPY MARKET SHARE, BASED ON PRODUCT, (2022 V/S 2029) (%)
      • FIGURE 66     EUROPEAN TEMPORARY AGENTS MARKET SHARE, BASED ON PRODUCTS (2022 V/S 2029) (%)
      • FIGURE 67     EUROPEAN PERMANENT AGENTS MARKET SHARE, BASED ON PRODUCTS (2022 V/S 2029) (%)
      • FIGURE 68     EUROPEAN PARTICLE AGENTS MARKET SHARE, BASED ON PRODUCTS (2022 V/S 2029) (%)
      • FIGURE 69     EUROPEAN COILS MARKET SHARE, BASED ON DEPLOYMENT, (2022 V/S 2029) (%)
      • FIGURE 70     EUROPEAN EMBOLOTHERAPY MARKET SHARE, BASED ON APPLICATION, (2022) (%)
      • FIGURE 71     EUROPEAN NEUROLOGY MARKET SHARE, BASED ON INDICATION, (2022 V/S 2029) (%)
      • FIGURE 72     EUROPEAN ONCOLOGY MARKET SHARE, BASED ON INDICATION, (2022 V/S 2029) (%)
      • FIGURE 73     EUROPEAN EMBOLOTHERAPY MARKET SHARE, BASED ON PROCEDURE, (2022 V/S 2029) (%)
      • FIGURE 74     EUROPEAN TACE MARKET SHARE, BASED ON THERAPY AGENTS, (2022 V/S 2029) (%)
      • FIGURE 75     EUROPEAN EMBOLOTHERAPY MARKET SHARE, BASED ON END-USER (2022 V/S 2029) (%)
      • FIGURE 76     EUROPEAN EMBOLOTHERAPY MARKET SHARE, BASED ON COUNTRY (2022 V/S 2029) (%)
      • FIGURE 77     GERMANY EMBOLOTHERAPY MARKET REVENUE, BASED ON PRODUCTS AND APPLICATION (2022 V/S 2029) ($MN)
      • FIGURE 78     GERMANY EMBOLOTHERAPY MARKET REVENUE, BASED ON PROCEDURE AND END-USERS (2022 V/S 2029) ($MN)
      • FIGURE 79     FRANCE EMBOLOTHERAPY MARKET REVENUE, BASED ON PRODUCTS AND APPLICATION (2022 V/S 2029) ($MN)
      • FIGURE 80     FRANCE EMBOLOTHERAPY MARKET REVENUE, BASED ON PROCEDURE AND END-USERS (2022 V/S 2029) ($MN)
      • FIGURE 81     ITALY EMBOLOTHERAPY MARKET REVENUE, BASED ON PRODUCTS AND APPLICATION (2022 V/S 2029) ($MN)
      • FIGURE 82     ITALY EMBOLOTHERAPY MARKET REVENUE, BASED ON PROCEDURE AND END-USERS (2022 V/S 2029) ($MN)
      • FIGURE 83     REST OF EUROPE EMBOLOTHERAPY MARKET REVENUE, BASED ON PRODUCTS AND APPLICATION (2022 V/S 2029) ($MN)
      • FIGURE 84     REST OF EUROPE EMBOLOTHERAPY MARKET REVENUE, BASED ON PROCEDURE AND END-USERS (2022 V/S 2029) ($MN)
      • FIGURE 85     ASIA-PACIFIC EMBOLOTHERAPY MARKET SHARE, BASED ON PRODUCT, (2022 V/S 2029) (%)
      • FIGURE 86     ASIA-PACIFIC TEMPORARY AGENTS MARKET SHARE, BASED ON PRODUCT (2022 V/S 2029) (%)
      • FIGURE 87     ASIA-PACIFIC PERMANENT AGENTS MARKET SHARE, BASED ON PRODUCTS (2022 V/S 2029) (%)
      • FIGURE 88     ASIA-PACIFIC PARTICLE AGENTS MARKET SHARE, BASED ON PRODUCTS (2022 V/S 2029) (%)
      • FIGURE 89     ASIA-PACIFIC COILS MARKET SHARE, BASED ON DEPLOYMENT, (2022 V/S 2029) (%)
      • FIGURE 90     ASIA-PACIFIC EMBOLOTHERAPY MARKET SHARE, BASED ON APPLICATION, (2022) (%)
      • FIGURE 91     ASIA-PACIFIC NEUROLOGY MARKET SHARE, BASED ON INDICATION, (2022 V/S 2029) (%)
      • FIGURE 92     ASIA-PACIFIC EMBOLOTHERAPY MARKET SHARE, BASED ON INDICATION, (2022 V/S 2029) (%)
      • FIGURE 93     ASIA-PACIFIC EMBOLOTHERAPY MARKET SHARE, BASED ON PROCEDURE, (2022 V/S 2029) (%)
      • FIGURE 94     ASIA-PACIFIC TACE MARKET SHARE, BASED ON THERAPY AGENTS, (2022 V/S 2029) (%)
      • FIGURE 95     ASIA-PACIFIC EMBOLOTHERAPY MARKET SHARE, BASED ON END-USER (2022 V/S 2029) (%)
      • FIGURE 96     ASIA-PACIFIC EMBOLOTHERAPY MARKET SHARE, BASED ON COUNTRY (2022 V/S 2029) (%)
      • FIGURE 97     JAPAN EMBOLOTHERAPY MARKET REVENUE, BASED ON PRODUCTS AND APPLICATION (2022 V/S 2029) ($MN)
      • FIGURE 98     JAPAN EMBOLOTHERAPY MARKET REVENUE, BASED ON PROCEDURE AND END-USERS (2022 V/S 2029) ($MN)
      • FIGURE 99     CHINA EMBOLOTHERAPY MARKET REVENUE, BASED ON PRODUCTS AND APPLICATION (2022 V/S 2029) ($MN)
      • FIGURE 100     CHINA EMBOLOTHERAPY MARKET REVENUE, BASED ON PROCEDURE AND END-USERS (2022 V/S 2029) ($MN)
      • FIGURE 101     INDIA EMBOLOTHERAPY MARKET REVENUE, BASED ON PRODUCT AND APPLICATION (2022 V/S 2029) ($MN)
      • FIGURE 102     INDIA EMBOLOTHERAPY MARKET REVENUE, BASED ON PROCEDURE AND END-USER (2022 V/S 2029) ($MN)
      • FIGURE 103     REST OF APAC EMBOLOTHERAPY MARKET REVENUE, BASED ON PRODUCTS AND APPLICATION (2022 V/S 2029) ($MN)
      • FIGURE 104     REST OF APAC EMBOLOTHERAPY MARKET REVENUE, BASED ON PROCEDURE AND END-USERS (2022 V/S 2029) ($MN)
      • FIGURE 105     ROW EMBOLOTHERAPY MARKET SHARE, BASED ON PRODUCTS, (2022 V/S 2029) (%)
      • FIGURE 106     ROW TEMPORARY AGENTS MARKET SHARE, BASED ON PRODUCT (2022 V/S 2029) (%)
      • FIGURE 107     ROW PERMANENT AGENTS MARKET SHARE, BASED ON PRODUCTS (2022 V/S 2029) (%)
      • FIGURE 108     ROW PARTICLE AGENTS MARKET SHARE, BASED ON PRODUCTS (2022 V/S 2029) (%)
      • FIGURE 109     ROW COILS MARKET SHARE, BASED ON DEPLOYMENT, (2022 V/S 2029) (%)
      • FIGURE 110     ROW EMBOLOTHERAPY MARKET SHARE, BASED ON APPLICATION, (2022) (%)
      • FIGURE 111     ROW NEUROLOGY MARKET SHARE, BASED ON INDICATION, (2022 V/S 2029) (%)
      • FIGURE 112     ROW EMBOLOTHERAPY MARKET SHARE, BASED ON INDICATION, (2022 V/S 2029) (%)
      • FIGURE 113     ROW EMBOLOTHERAPY MARKET SHARE, BASED ON PROCEDURE, (2022 V/S 2029) (%)
      • FIGURE 114     ROW TACE MARKET SHARE, BASED ON THERAPY AGENTS, (2022 V/S 2029) (%)
      • FIGURE 115     ROW EMBOLOTHERAPY MARKET SHARE, BASED ON END-USER (2022 V/S 2029) (%)
      • FIGURE 116     ROW EMBOLOTHERAPY MARKET SHARE, BASED ON COUNTRY (2022 V/S 2029) (%)
      • FIGURE 117     BRAZIL EMBOLOTHERAPY MARKET REVENUE, BASED ON PRODUCTS AND APPLICATION (2022 V/S 2029) ($MN)
      • FIGURE 118     BRAZIL EMBOLOTHERAPY MARKET REVENUE, BASED ON PROCEDURE AND END-USERS (2022 V/S 2029) ($MN)
      • FIGURE 119     REST OF SOUTH AMERICA EMBOLOTHERAPY MARKET REVENUE, BASED ON PRODUCTS AND APPLICATION (2022 V/S 2029) ($MN)
      • FIGURE 120     REST OF SOUTH AMERICA EMBOLOTHERAPY MARKET REVENUE, BASED ON PROCEDURE AND END-USERS (2022 V/S 2029) ($MN)
      • FIGURE 121     MIDDLE EAST AND AFRICA EMBOLOTHERAPY MARKET REVENUE, BASED ON PRODUCTS AND APPLICATION (2022 V/S 2029) ($MN)
      • FIGURE 122     MIDDLE EAST AND AFRICA EMBOLOTHERAPY MARKET REVENUE, BASED ON PROCEDURE AND END-USER (2022 V/S 2029) ($MN)
      • FIGURE 123     KEY GROWTH STRATEGIES (2020-2022)
      • FIGURE 124     SWOT: BALT GROUP
      • FIGURE 125     SWOT: BOSTON SCIENTIFIC CORPORATION
      • FIGURE 126     SWOT: SIRTEX MEDICAL INC.
      • FIGURE 127     SWOT: JOHNSON & JOHNSON
      • FIGURE 128     SWOT: KANEKA CORPORATION
      • FIGURE 129     SWOT: MEDTRONIC, PLC
      • FIGURE 130     SWOT: MERIT MEDICAL SYSTEMS, INC.
      • FIGURE 131     SWOT: PENUMBRA
      • FIGURE 132     SWOT: STRYKER
      • FIGURE 133     SWOT: TERUMO CORPORATION

      LIST OF COMPANIES MENTIONED IN THE REPORT

      • 1     ACANDIS GMBH
      • 2     ANDRATEC GMBH
      • 3     ARTIO MEDICAL
      • 4     ARTVENTIVE MEDICAL GROUP, INC.
      • 5     ASAHI INTECC CO., LTD
      • 6     B.BRAUN MELSUNGEN
      • 7     BALT GROUP
      • 8     BECTON, DICKINSON AND COMPANY
      • 9     BOSTON SCIENTIFIC CORP.
      • 10     BRAILE BIOMEDICA INDUSTRIA
      • 11     CERUS ENDOVASCULAR
      • 12     COOK MEDICAL
      • 13     CRANNMED LIMITED
      • 14     EMBOLX, INC.
      • 15     GEM SRL
      • 16     GUERBET
      • 17     IMBIOTECHNOLOGIES, LTD.
      • 18     INVAMED
      • 19     JOHNSON & JOHNSON
      • 20     KANEKA CORP.
      • 21     LEPU MEDICAL
      • 22     LIFETECH SCIENTIFIC CORP.
      • 23     MEDTRONIC
      • 24     MERIL LIFE SCIENCES
      • 25     MERIT MEDICAL
      • 26     MICROPORT
      • 27     NEXT BIOMEDICAL CO., LTD
      • 28     OKAMI MEDICAL, INC
      • 29     PEIJIA MEDICAL
      • 30     PENUMBRA, INC.
      • 31     PFIZER
      • 32     PHARMACEPT GMBH
      • 33     PHENOX
      • 34     PIOLAX MEDICAL DEVICES, INC.
      • 35     PL MICROMED CO., LTD
      • 36     QMEDICS AG
      • 37     RAPID MEDICAL
      • 38     SCITECH MEDICAL
      • 39     SHAPE MEMORY MEDICAL
      • 40     SIEMENS HEALTHINEERS (VARIAN)
      • 41     SIRTEX
      • 42     SOLID MEDICAL SYSTEMS
      • 43     SPARTAN MICRO
      • 44     STRYKER
      • 45     SUZHOU HENGRUI CALLISYN BIOMEDICAL CO., LTD.
      • 46     SUZHOU HENGRUI DISHENG MEDICAL CO., LTD
      • 47     TELEFLEX
      • 48     TERUMO CORPORATION
      • 49     WALLABY MEDICAL
      • 50     WEGO HEALTHCARE (SHENZHEN) CO., LTD.
      • 51     ZYLOX-TONBRIDGE MEDICAL TECH.CO. LTD